Compositions and methods for treating an inflammatory disease or disorder
The invention relates to compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof. In certain aspects, the invention relates to immunogenic compositions (e.g., vaccines) to diminish the number or pathogenic effects of one or more bacteria associated with the development or progression of an inflammatory disease or disorder.
1. A method of treating inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject non-colitogenic bacteria, wherein the non-colitogenic bacteria do not contribute to the development or progression of IBD in the subject, and wherein the subject has been diagnosed with IBD via detection of secretory antibody-bound colitogenic bacteria that do contribute to the development or progression of IBD.
2. The method of claim 1 , further comprising the step of administering to the subject at least one therapy to diminish the number of at least one strain of at least one species of bacteria that is associated with the development or progression of the IBD.
3. The method of claim 1 , wherein the non-colitogenic bacteria are administered in a dosage range selected from about 10 4 to about 10 6 CFU per administration or about 10 6 to about 10 10 CFU per administration.
4. The method of claim 1 , wherein the non-colitogenic bacteria are identified from a healthy subject that does not have IBD.
5. The method of claim 1 , wherein the non-colitogenic bacteria are administered as live bacteria.
6. The method of claim 1 , wherein the non-colitogenic bacteria are administered in a buffering agent selected from sodium bicarbonate, milk, yogurt, infant formula, and other dairy products.
7. The method of claim 1 , wherein the non-colitogenic bacteria are mixed with a carrier and applied to a liquid or to food for administration.
8. The method of claim 1 , wherein the non-colitogenic bacteria are secretory antibody-bound and are derived from a subject who does not suffer from IBD.
9. The method of claim 1 , wherein the non-colitogenic and/or colitogenic bacteria are selected from the group consisting of Akkermansia muciniphila, Bacteroides acidifaciens, Bacteroides coprophilus, Bacteroides fragilis, Bacteroides ovatus, Bacteroides uniformis, Bifidobacterium adolescentis, Blautia obeum, Blautia producta, Clostridium perfringens, Collinsella aerofaciens, Collinsella stercoris, Coprococcus catus, Dorea formicigenerans, Eggerthella lenta, Eubacterium biforme, Eubacterium dolichum, Faecalibacterium prausnitzii, Haemophilus parainfluenzae, Lactobacillus reuteri, Lactobacillus mucosae, Lactobacillus zeae, Mitsuokella multacida, Parabacteroides distasonis, Peptostreptococcus anaerobius, Prevotella copri, Prevotella stercorea, Roseburia faecis, Ruminococcus bromii, Ruminococcus gnavus, Ruminococcus torques, Streptococcus anginosus, Streptococcus luteciae, Sutterella, Turicibacter, Veillonella parvula , and Veillonella dispar.
10. The method of claim 9 , wherein the non-colitogenic and/or colitogenic bacteria is Bacteroides fragilis.
11. The method of claim 1 , further comprising administering to the subject at least one therapy to diminish the number or pathogenic effects of the colitogenic bacteria present in the subject.
12. The method of claim 11 , wherein the at least one therapy is selected from the group consisting of a vaccine, an antibiotic, and a passive immunotherapy.
13. The method of claim 12 , wherein the at least one therapy is a vaccine.
14. The method of claim 12 , wherein the at least one therapy is a passive immunotherapy.